FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions refers to pharmaceutics and can be used for treating cell proliferation disorders. Disclosed is a water-insoluble controlled-release pattern recognition receptor (PRRA) agonist or a pharmaceutically acceptable salt thereof, wherein said water-insoluble controlled-release PRRA releases one or more PRRAs, and at least 25% of the amount of PRRA remains locally in such tissue 3 days after interstitial administration, wherein the water-insoluble PRRA contains a carrier moiety Z, with which one or more fragments -L2-L1-D are conjugated, where: each -L2- is individually a C1-20 alkyl chain, which is optionally interrupted by one or more groups independently selected from -O-, -T- and -C(O)N(Ry1)-; each -L1- is individually a linker fragment with which -D is reversibly and covalently conjugated; each D is resiquimod; Z is a water-insoluble PEG hydrogel. Also disclosed is a pharmaceutical composition containing said water-insoluble PRRA and at least one excipient.
EFFECT: group of inventions provides effective treatment regimens with TLR agonists, higher local concentrations of PRRA for an extended period of time while maintaining low systemic concentrations of PRRA, which minimizes side effects.
11 cl, 17 ex
Title | Year | Author | Number |
---|---|---|---|
IL-2 CONJUGATES | 2019 |
|
RU2809259C2 |
ENPP1 INHIBITORS AND METHODS OF MODULATING THE IMMUNE RESPONSE | 2018 |
|
RU2800798C2 |
COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT | 2018 |
|
RU2805355C2 |
COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS | 2019 |
|
RU2810717C2 |
CNP PRODRUGS | 2016 |
|
RU2824988C1 |
METHOD OF TREATING OR CONTROL OF HYPOPARATHYROIDUS USING PARATHROOID HORMONE (PTH) CONJUGATE | 2019 |
|
RU2806753C2 |
BENZAZEPINE COMPOUNDS, CONJUGATES AND THEIR USE | 2018 |
|
RU2780334C2 |
3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | 2021 |
|
RU2825312C1 |
HETEROARYLSULPHONYL-SUBSTITUTED PYRIDINES AND APPLICATION THEREOF IN TREATMENT OF CANCER | 2018 |
|
RU2772935C2 |
HETEROCYCLYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN TREATMENT OF CANCER | 2018 |
|
RU2777596C2 |
Authors
Dates
2024-04-18—Published
2020-01-03—Filed